Plavix - Biotech, Pharma and Life Science Channel
Plavix is a clot-busting drug, produced by Bristol-Myers Squibb Company, and reached annual sales in 2009 of $4.2m, making the third highest drug in the world (based on 2009 annual sales).
Prescriptions for Plavix are intended to lower a patients risk of cardiovascular disease or a cerebrovascular accident. It is taken by people who are already perceived at high risk of these problems, due to previous such events, smoking or other risk factors. These are sadly very common in Western populations, and might explain the high sales of this drug.
Source; Adapted from BioPortfolio and Plavix.com
Add the Plavix News Channel to your RSS reader;
Follow the Plavix Twitter feed;
News Articles
Low-risk aortic valve patients are maintained with aspirin and clopidogrel only On-X® Life Technologies, Inc. (On-X LTI) announced today that enrollment for the...
Sanofi: Q1 2013 business EPS(1) impacted by exclusivity losses in prior year
PARIS, May 2, 2013 /PRNewswire/ -- Sanofi (NYSE: SNY; EURONEXT: SAN) Q1 2013 Change
Consumer Reports: So Many Drugstores, So Many Prices; New Report Finds Price Mayhem At The Pharmacy
Tips for getting the best prices when you shop at the pharmacy; plus, why it pays to shop like a country mouse YONKERS, N.Y., March 28, 2013 /PRNewswire-USNewswire/ -- Con...
Aggredyne Increases IP Portfolio to Four Patents
Aggredyne, Inc., a Houston-based biomedical diagnostics company that is defining a new standard for platelet function, has added a fourth patent to its intellectual property portf...
BARCELONA, Spain, November 5, 2012 /PRNewswire/ -- Life Science Entrepreneurs S.L.U., a company dedicated to the early-stage development of high-risk/very high return ventures, announced today the co...
Aggredyne Names Two New Directors
Brady F. Carruth, president of the Wortham Foundation, and Edgar C. “Red” Griffin, founder of Grifco Transportation, have joined the Aggredyne, Inc., board of directors. Aggre...
MIAMI, Oct. 23, 2012 /PRNewswire/ -- Daiichi Sankyo, Inc. and Eli Lilly and Company (NYSE: LLY) today announced new results of two retrospective, observational, comparative effectiveness studies...
Sanofi and Bristol-Myers Squibb Announce Restructuring of Alliance Agreement
Sanofi (EURONEXT: SAN and NYSE: SNY) and Bristol-Myers Squibb Company (NYSE: BMY) today announced they have restructured their successful long-term alliance following the loss of...
BI-LO Adds The Generic Form Of PLAVIX (clopidogrel) To Its $4/$10 Generics Prescription Program
JACKSONVILLE, Fla., Sept. 28, 2012 /PRNewswire/ -- Today BI-LO announced the generic form of PLAVIX® (clopidogrel)* is now available for $4 for 30-day and $10 for 90-day prescriptions as part of...
HealthWarehouse.com Reports 38% Year-Over-Year Revenue Growth in the First Quarter 2012
CINCINNATI, Sept. 5, 2012 /PRNewswire/ -- HealthWarehouse.com, Inc. (OTC: HEWA) a leading VIPPS accredited retail mail-order pharmacy, today announced its financial results for the first quarter...
Events
None
Companies
None
Clinical Trials
Role of Plavix in Hemorrhagic and Ischemic Complications of Catheterization.
Patients who have stents placed in their coronary arteries require treatment with at least two medications to prevent platelets from sticking to the stainless steel stent and forming a blo...
Acute myocardial infarction is generally caused by a thrombotic occlusion of coronary arteries. Primary aim of early therapy is a fast and complete reperfusion of the infarcted myocardium,...
PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes
The purpose of the trial is to determine if extended-release dipyridamole + aspirin [Aggrenox, Asasa ntin] is superior to clopidogrel [Plavix], and if telmisartan [Micardis, Gliosartan, Ki...
Clopidogrel PGX Bench to Bedside
Clopidogrel (also known as Plavix) is used commonly in patients to prevent heart attacks and conditions caused by blood clots. Although clopidogrel works in many individuals, some people...
Effect of Abrupt Plavix® Discontinuation on Platelet Function
The well established importance of regular administration of antiplatelet drugs stands on firm grounds, as large meta-analyses have shown these therapies to significantly reduce the risk o...
A large number of patients are currently on Antiplatelet inhibition using aspirin or Plavix therapy (A Thieno pyridine - ADP mediated platelet inhibitor). A group of these patients often r...
Bridging Therapy in Patients at High Risk for Stent Thrombosis Undergoing Surgery
Patients who have undergone placement of coronary stents require dual antiplatelet therapy with Plavix and aspirin to prevent the serious complication of in-stent thrombosis. Some of these...
Pharmacodynamics of CGT 2168 Compared With Plavix®
CG106 is a Phase I open-label, randomized, multiple-dose, two-way crossover study to characterize the pharmacodynamics and pharmacokinetics of the investigational fixed-dose combination pr...
Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1)
The purpose of the COGENT-1 clinical trial is to determine whether CGT-2168 (clopidogrel and omeprazole) compared to clopidogrel is safe and effective in reducing the incidence of gastroin...
Association of Clopidogrel Therapy and Stent Thrombosis
The purpose of REAL-LATE (Correlation of Clopidogrel Therapy Discontinuation in REAL-world Patients Treated with Drug-Eluting Stent Implantation and Late Coronary Arterial Thrombotic Event...
PubMed Articles
Quantitative determination of clopidogrel and its metabolites in biological samples: A mini-review.
Clopidogrel has been applied in antiplatelet therapy since 1998 and is the thienopyridine with the largest clinical experience. By 2011, clopidogrel (Plavix(®)) was the second top-selling drug in the...
Dual antiplatelet treatment in patients candidates for abdominal surgery.
Dual antiplatelet treatment in patients candidates for abdominal surgery With the increasing diffusion of percutaneous interventions (PCI), surgeons are often faced with the problem of operating on pa...
Emergency bypass post percutaneous atrial ablation: a case report.
A 34-year-old male undergoing percutaneous atrial ablation procedure for paroxysmal fibrillation required emergency sternotomy for cardiac tamponade. The patient had been anticoagulated and had receiv...
General thoracic surgery is safe in patients taking clopidogrel (Plavix).
BACKGROUND: The objective of this study was to assess the safety of general thoracic surgery in patients taking antiplatelet (clopidogrel) therapy. METHODS: A prospective study was conducted of consec...
Three peri-substituted trisulfide-2-oxides are prepared by treatment of 1,8-naphthalene dithiols with thionyl chloride and pyridine. The 1,2,3-trithiane-2-oxide ring adopts a sofa conformation in the...
The discovery of the role of P2Y(12) receptor in platelet aggregation leads to a new anti-thrombotic drug Plavix; however, little is known about non-platelet P2Y receptors in thrombosis. This study te...
Multiple comparisons of drug efficacy between subgroups defined by genetic polymorphisms.
In contrast to using genome-wide association studies to discover associations between genes or single-nucleotide polymorphisms in the genome with disease status or outcome, some recent pharmacogenomic...
Videos
Plavix (Clopidogrel): Know Your Drug
In this week's episode of Know Your Drug, Brothers Matt Diehl and Nickolas Smithmyer discuss the prescription drug Plavix (Clopidogrel). Plavix is commonly p...
